Literature DB >> 26239197

Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells.

I Hermanova1, A Arruabarrena-Aristorena2, K Valis3,4, H Nuskova5, M Alberich-Jorda6, K Fiser1, S Fernandez-Ruiz2, D Kavan3,4, A Pecinova5, M Niso-Santano7,8, M Zaliova1, P Novak3,4, J Houstek5, T Mracek5, G Kroemer7,8,9,10, A Carracedo2,11,12, J Trka1,13, J Starkova1.   

Abstract

l-asparaginase (ASNase), a key component in the treatment of childhood acute lymphoblastic leukemia (ALL), hydrolyzes plasma asparagine and glutamine and thereby disturbs metabolic homeostasis of leukemic cells. The efficacy of such therapeutic strategy will depend on the capacity of cancer cells to adapt to the metabolic challenge, which could relate to the activation of compensatory metabolic routes. Therefore, we studied the impact of ASNase on the main metabolic pathways in leukemic cells. Treating leukemic cells with ASNase increased fatty-acid oxidation (FAO) and cell respiration and inhibited glycolysis. FAO, together with the decrease in protein translation and pyrimidine synthesis, was positively regulated through inhibition of the RagB-mTORC1 pathway, whereas the effect on glycolysis was RagB-mTORC1 independent. As FAO has been suggested to have a pro-survival function in leukemic cells, we tested its contribution to cell survival following ASNase treatment. Pharmacological inhibition of FAO significantly increased the sensitivity of ALL cells to ASNase. Moreover, constitutive activation of the mammalian target of rapamycin pathway increased apoptosis in leukemic cells treated with ASNase, but did not increase FAO. Our study uncovers a novel therapeutic option based on the combination of ASNase and FAO inhibitors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26239197     DOI: 10.1038/leu.2015.213

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  59 in total

Review 1.  Upstream and downstream of mTOR.

Authors:  Nissim Hay; Nahum Sonenberg
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

2.  Amino acid levels following L-asparagine amidohydrolase (EC.3.5.1.1) therapy.

Authors:  H K Miller; J S Salser; M E Balis
Journal:  Cancer Res       Date:  1969-01       Impact factor: 12.701

3.  mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events.

Authors:  Marina K Holz; Bryan A Ballif; Steven P Gygi; John Blenis
Journal:  Cell       Date:  2005-11-18       Impact factor: 41.582

4.  mTORC1 controls fasting-induced ketogenesis and its modulation by ageing.

Authors:  Shomit Sengupta; Timothy R Peterson; Mathieu Laplante; Stephanie Oh; David M Sabatini
Journal:  Nature       Date:  2010-12-23       Impact factor: 49.962

5.  In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions.

Authors:  R Pieters; A H Loonen; D R Huismans; G J Broekema; M W Dirven; M W Heyenbrok; K Hählen; A J Veerman
Journal:  Blood       Date:  1990-12-01       Impact factor: 22.113

6.  Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.

Authors:  Dan Douer; Henry Yampolsky; Lewis J Cohen; Kristy Watkins; Alexandra M Levine; Antonia P Periclou; Vassilios I Avramis
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

7.  Suppression of the mitochondrial oxidation of (-)-palmitylcarnitine by the malate-aspartate and alpha-glycerophosphate shuttles.

Authors:  L Lumeng; J Bremer; E J Davis
Journal:  J Biol Chem       Date:  1976-01-25       Impact factor: 5.157

8.  Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis.

Authors:  Aaron M Robitaille; Stefan Christen; Mitsugu Shimobayashi; Marion Cornu; Luca L Fava; Suzette Moes; Cristina Prescianotto-Baschong; Uwe Sauer; Paul Jenoe; Michael N Hall
Journal:  Science       Date:  2013-02-21       Impact factor: 47.728

9.  Apoptotic efficacy of etomoxir in human acute myeloid leukemia cells. Cooperation with arsenic trioxide and glycolytic inhibitors, and regulation by oxidative stress and protein kinase activities.

Authors:  María Cristina Estañ; Eva Calviño; Susana Calvo; Beatriz Guillén-Guío; María Del Carmen Boyano-Adánez; Elena de Blas; Eduardo Rial; Patricio Aller
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

10.  Regulation of TORC1 by Rag GTPases in nutrient response.

Authors:  Eunjung Kim; Pankuri Goraksha-Hicks; Li Li; Thomas P Neufeld; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2008-07-06       Impact factor: 28.824

View more
  16 in total

1.  PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2.

Authors:  Natalie J German; Haejin Yoon; Rushdia Z Yusuf; J Patrick Murphy; Lydia W S Finley; Gaëlle Laurent; Wilhelm Haas; F Kyle Satterstrom; Jlenia Guarnerio; Elma Zaganjor; Daniel Santos; Pier Paolo Pandolfi; Andrew H Beck; Steven P Gygi; David T Scadden; William G Kaelin; Marcia C Haigis
Journal:  Mol Cell       Date:  2016-09-15       Impact factor: 17.970

2.  Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells.

Authors:  Larissa Menezes Dos Reis; Douglas Adamoski; Rodolpho Ornitz Oliveira Souza; Carolline Fernanda Rodrigues Ascenção; Krishina Ratna Sousa de Oliveira; Felipe Corrêa-da-Silva; Fábio Malta de Sá Patroni; Marília Meira Dias; Sílvio Roberto Consonni; Pedro Manoel Mendes de Moraes-Vieira; Ariel Mariano Silber; Sandra Martha Gomes Dias
Journal:  J Biol Chem       Date:  2019-04-30       Impact factor: 5.157

Review 3.  Targeting metabolic dependencies in pediatric cancer.

Authors:  Sameer H Issaq; Christine M Heske
Journal:  Curr Opin Pediatr       Date:  2020-02       Impact factor: 2.856

Review 4.  Fatty acid oxidation: An emerging facet of metabolic transformation in cancer.

Authors:  Yibao Ma; Sarah M Temkin; Adam M Hawkridge; Chunqing Guo; Wei Wang; Xiang-Yang Wang; Xianjun Fang
Journal:  Cancer Lett       Date:  2018-08-10       Impact factor: 8.679

5.  Reprogramming of leukemic cell metabolism through the naphthoquinonic compound Quambalarine B.

Authors:  Karel Vališ; Valéria Grobárová; Lucie Hernychová; Martina Bugáňová; Daniel Kavan; Martin Kalous; Jiří Černý; Eva Stodůlková; Marek Kuzma; Miroslav Flieger; Jan Černý; Petr Novák
Journal:  Oncotarget       Date:  2017-10-07

6.  Autophagy is required for cell survival under L-asparaginase-induced metabolic stress in acute lymphoblastic leukemia cells.

Authors:  H Takahashi; J Inoue; K Sakaguchi; M Takagi; S Mizutani; J Inazawa
Journal:  Oncogene       Date:  2017-03-27       Impact factor: 9.867

7.  Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase.

Authors:  Katerina Hlozkova; Alena Pecinova; Natividad Alquezar-Artieda; David Pajuelo-Reguera; Marketa Simcikova; Lenka Hovorkova; Katerina Rejlova; Marketa Zaliova; Tomas Mracek; Alexandra Kolenova; Jan Stary; Jan Trka; Julia Starkova
Journal:  BMC Cancer       Date:  2020-06-05       Impact factor: 4.430

8.  Cloning and expression of L-asparaginase from Bacillus tequilensis PV9W and therapeutic efficacy of Solid Lipid Particle formulations against cancer.

Authors:  Ganeshan Shakambari; Rai Sameer Kumar; Balasubramaniem Ashokkumar; Venkatachalam Ganesh; Vairathevar Sivasamy Vasantha; Perumal Varalakshmi
Journal:  Sci Rep       Date:  2018-12-20       Impact factor: 4.379

9.  Levocarnitine does not impair chemotherapy cytotoxicity against acute lymphoblastic leukemia.

Authors:  Jessica L Sea; Etan Orgel; Ting Chen; Rebecca L Paszkiewicz; Abigail S Krall; Matthew J Oberley; Linsey Stiles; Steven D Mittelman
Journal:  Leuk Lymphoma       Date:  2019-09-16

Review 10.  Metabolic dependencies and vulnerabilities in leukemia.

Authors:  Marissa Rashkovan; Adolfo Ferrando
Journal:  Genes Dev       Date:  2019-11-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.